News
Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients ...
The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.
23h
GlobalData on MSNHansa’s Idefirix shows potential as pre-treatment to ElevidysHansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.
After Loomer targeted surgeon general nominee and Kennedy ally Casey Means, Means’s brother, Calley, suggested that Loomer’s ...
The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...
While MSN reports that Sarepta’s stock price began to rise on Monday on the heels of the announcement, 5 the company is still ...
I understand the heartbreak of watching someone you love spiral. But compassion cannot mean locking people up,” writes a STAT ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart ...
Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results